Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension of SAR153191 with DMARDs in active rheumatoid arthritis
2010-019262-86Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sarilumab in rheumatoid arthritis (RA), sponsored by Sanofi. Primary endpoint: Long-term safety of SAR153191. Started Apr 2010; status: completed.
02
Drugs
sarilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-019262-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019262-86.